Occult Axillary Node Metastases in Breast Cancer: Their Detection and Prognostic Significance

Overview

Journal Br J Cancer

Specialty Oncology

Date 1996 Jan 1

PMID 8554990

Citations 32

Authors

M A McGuckin

M C Cummings

M D Walsh

B G Hohn

I C Bennett

R G Wright

Affiliations

Soon will be listed here.

Abstract

Although the presence of axillary node metastases in breast cancer is a key prognostic indicator and may influence treatment decisions, a significant proportion of patients diagnosed as axillary node negative (ANN) using standard histopathological techniques may have occult nodal metastases (OMs). A combination of limited step-sectioning (4 x 100 microns intervals) and immunohistochemical staining (with cytokeratin (MNF.116) and MUC1 (BC2) antibodies) was used to detect OM in a retrospective series of 208 ANN patients. OMs were found in 53 patients (25%), and both step-sectioning and immunohistochemical detection significantly improved detection (P < 0.05). Detection using BC2 (25%) was superior to MNF.116 (18%) and haematoxylin and eosin (H&E) (8%). OMs were found in 51 patients using only the first and deepest sectioning levels and BC2 staining. OMs were more frequently found in lobular (38%) than ductal carcinoma (25%), and more frequently in women less than 50 years (41%) than in older women (19%). Univariate overall and disease-free survival analyses showed that the presence, size and number of OM had prognostic significance as did tumour size (disease-free only) and histological and nuclear grade (P > 0.05). Cox multivariate proportional hazard regression analyses showed that the presence and increasing size of OMs were significantly associated with poorer disease-free survival, independently of other prognostic factors (P < 0.05). However there was not a significant independent association of the presence of occult metastases with overall survival (P = 0.11). These findings have important implications with regard to selection of ANN patients for adjuvant therapy.

Citing Articles

The Role of Adjuvant Therapy for the Treatment of Micrometastases in Endometrial Cancer: A Systematic Review and Meta-Analysis.

Ronsini C, Napolitano S, Iavarone I, Fumiento P, Vastarella M, Reino A J Clin Med. 2024; 13(5).

PMID: 38592342 PMC: 10932314. DOI: 10.3390/jcm13051496.

Does the Presence of Cytokeratin Positive Individual Tumor Cells (N) in Sentinel Lymph Nodes Affect Clinical Outcomes in Breast Cancer Patients Treated with Accelerated Partial Breast Irradiation.

Smith J, Leonard C, Carter D, Tole S Breast Cancer (Dove Med Press). 2021; 13:513-517.

PMID: 34512014 PMC: 8413089. DOI: 10.2147/BCTT.S318197.

Prognostic significance of occult lymph node metastases in breast cancer: a meta-analysis.

Wang G, Zhang S, Wang M, Liu L, Liu Y, Tang L BMC Cancer. 2021; 21(1):875.

PMID: 34330233 PMC: 8325175. DOI: 10.1186/s12885-021-08582-1.

Oncologic impact of micrometastases or isolated tumor cells in sentinel lymph nodes of patients with endometrial cancer: a meta-analysis.

Gomez-Hidalgo N, Ramirez P, Ngo B, Perez-Hoyos S, Coreas N, Sanchez-Iglesias J Clin Transl Oncol. 2019; 22(8):1272-1279.

PMID: 31863354 PMC: 7992114. DOI: 10.1007/s12094-019-02249-x.

Increased risk of recurrence associated with certain risk factors in breast cancer patients after DIEP-flap reconstruction and lipofilling-a matched cohort study with 200 patients.

Fertsch S, Hagouan M, Munder B, Schulz T, Abu-Ghazaleh A, Schaberick J Gland Surg. 2017; 6(4):315-323.

PMID: 28861370 PMC: 5566658. DOI: 10.21037/gs.2017.03.11.

References

Wilkinson E, Hause L . Probability in lymph node sectioning. Cancer. 1974; 33(5):1269-74. DOI: 10.1002/1097-0142(197405)33:5<1269::aid-cncr2820330512>3.0.co;2-x. View

McGuckin M, Walsh M, Hohn B, Ward B, Wright R . Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Hum Pathol. 1995; 26(4):432-9. DOI: 10.1016/0046-8177(95)90146-9. View

Wilkinson E, Hause L, Hoffman R, KUZMA J, Rothwell D, DONEGAN W . Occult axillary lymph node metastases in invasive breast carcinoma: characteristics of the primary tumor and significance of the metastases. Pathol Annu. 1982; 17 Pt 2:67-91. View

Harris M, Howell A, Chrissohou M, Swindell R, Hudson M, SELLWOOD R . A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. Br J Cancer. 1984; 50(1):23-30. PMC: 1976917. DOI: 10.1038/bjc.1984.135. View

Wells C, Heryet A, BROCHIER J, Gatter K, Mason D . The immunocytochemical detection of axillary micrometastases in breast cancer. Br J Cancer. 1984; 50(2):193-7. PMC: 1976865. DOI: 10.1038/bjc.1984.162. View

Trojani M, de Mascarel I, Bonichon F, Coindre J, Delsol G . Micrometastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and prognostic significance. Br J Cancer. 1987; 55(3):303-6. PMC: 2001759. DOI: 10.1038/bjc.1987.59. View

Trojani M, de Mascarel I, Coindre J, Bonichon F . Micrometastases to axillary lymph nodes from invasive lobular carcinoma of breast: detection by immunohistochemistry and prognostic significance. Br J Cancer. 1987; 56(6):838-9. PMC: 2002396. DOI: 10.1038/bjc.1987.301. View

Friedman S, Bertin F, Mouriesse H, Benchabat A, Genin J, Sarrazin D . Importance of tumor cells in axillary node sinus margins ('clandestine' metastases) discovered by serial sectioning in operable breast carcinoma. Acta Oncol. 1988; 27(5):483-7. DOI: 10.3109/02841868809093575. View

Raymond W, Leong A . Immunoperoxidase staining in the detection of lymph node metastases in stage I breast cancer. Pathology. 1989; 21(1):11-5. DOI: 10.3109/00313028909059522. View

10.

Xing P, Tjandra J, Stacker S, Teh J, Thompson C, McLaughlin P . Monoclonal antibodies reactive with mucin expressed in breast cancer. Immunol Cell Biol. 1989; 67 ( Pt 3):183-95. DOI: 10.1038/icb.1989.29. View

11.

Xing P, Reynolds K, Tjandra J, Tang X, McKenzie I . Synthetic peptides reactive with anti-human milk fat globule membrane monoclonal antibodies. Cancer Res. 1990; 50(1):89-96. View

12.

Nio Y, Zighelboim J, Berek J, Bonavida B . Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers. Nat Immun Cell Growth Regul. 1990; 9(4):283-96. View

13.

Dearnaley D, Ormerod M, Sloane J . Micrometastases in breast cancer: long-term follow-up of the first patient cohort. Eur J Cancer. 1991; 27(3):236-9. DOI: 10.1016/0277-5379(91)90504-7. View

14.

Cote R, Rosen P, Lesser M, Old L, Osborne M . Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol. 1991; 9(10):1749-56. DOI: 10.1200/JCO.1991.9.10.1749. View

15.

Elston C, Ellis I . Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19(5):403-10. DOI: 10.1111/j.1365-2559.1991.tb00229.x. View

16.

Galea M, Athanassiou E, Bell J, Dilks B, Robertson J, Elston C . Occult regional lymph node metastases from breast carcinoma: immunohistological detection with antibodies CAM 5.2 and NCRC-11. J Pathol. 1991; 165(3):221-7. DOI: 10.1002/path.1711650305. View

17.

Byrne J, Horgan P, England S, Callaghan J, Given H . A preliminary report on the usefulness of monoclonal antibodies to CA 15-3 and MCA in the detection of micrometastases in axillary lymph nodes draining primary breast carcinoma. Eur J Cancer. 1992; 28(2-3):658-60. DOI: 10.1016/s0959-8049(05)80120-0. View

18.

Fisher B, Redmond C . Systemic therapy in node-negative patients: updated findings from NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst Monogr. 1992; (11):105-16. View

19.

Stewart H . The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group. J Natl Cancer Inst Monogr. 1992; (11):117-20. View

20.

McGuire W, Tandon A, Allred D, Chamness G, Ravdin P, Clark G . Treatment decisions in axillary node-negative breast cancer patients. J Natl Cancer Inst Monogr. 1992; (11):173-80. View